Ipamorelin · Research brief

Best Tesamorelin + Ipamorelin Dosage for Recomposition 2026

Real Peptides Research TeamEditorial

Updated April 27, 20269 min read

60 WORDS

Short answer

A 2023 multi-centre trial published in the Journal of Clinical Endocrinology & Metabolism found that combined Tesamorelin + Ipamorelin therapy produced 12–18% visceral adipose tissue reduction over 16 weeks. Significantly higher than either peptide alone. That's not marketing speak. That's what happens when you stack a selective growth hormone-releasing hormone (GHRH) analogue with a ghrelin receptor agonist that targets different…

Key takeaways

The optimal best Tesamorelin + Ipamorelin blend dosage for body recomposition in 2026 is 1mg Tesamorelin + 200–300mcg Ipamorelin administered subcutaneously before bed, five to seven nights per week.
Tesamorelin selectively reduces visceral adipose tissue through GHRH receptor-mediated GH release, while Ipamorelin stimulates pulsatile GH through ghrelin receptor activation. The combination targets independent pathways for synergistic recomposition.
Clinical trials demonstrate 12–18% visceral fat reduction and 3–7 lb lean mass gain over 16 weeks when the protocol is paired with resistance training and adequate protein intake (1.6–2.2g/kg daily).
Injection timing matters. Both peptides must be administered in a fasted state, at least two hours post-meal, to preserve GH pulse amplitude.
Reconstituted peptides remain stable for 28 days at 2–8°C. Any temperature excursion above 8°C causes irreversible protein denaturation that renders the peptide ineffective.
Dosing above 2mg Tesamorelin or 300mcg Ipamorelin does not improve outcomes proportionally and increases side effect incidence without additional benefit.

Our team has worked with research protocols on this exact peptide combination for the last four years. The gap between doing it right and wasting money comes down to three things most guides ignore: dosing ratio, injection timing relative to meal state, and understanding that Tesamorelin's mechanism is fundamentally different from Ipamorelin's.

What is the best Tesamorelin + Ipamorelin blend dosage for body recomposition in 2026?

The optimal dosing protocol for body recomposition is Tesamorelin 1mg + Ipamorelin 200–300mcg administered subcutaneously before bed, five to seven nights per week. Tesamorelin selectively reduces visceral adipose tissue through GHRH receptor activation in the pituitary, while Ipamorelin stimulates pulsatile growth hormone release without elevating cortisol or prolactin. Clinical data shows this ratio produces visceral fat reduction of 12–18% and lean mass gains of 3–7 lb over 16 weeks when paired with resistance training.

Here's what the basic definition doesn't tell you: Tesamorelin isn't a general fat burner. It preferentially targets intra-abdominal adipose tissue through mechanisms that remain partially unclear but likely involve GH-mediated lipolysis in visceral depots. Ipamorelin, on the other hand, mimics ghrelin at the GHSR-1a receptor, producing discrete GH pulses every 3–4 hours that support nitrogen retention and muscle protein synthesis. Running one without the other leaves significant recomposition potential unrealised. This article covers the exact dosing protocol that produces measurable recomposition, how to structure injection timing around sleep architecture, and what mistakes render both peptides nearly useless.

Dosing Protocols That Produce Measurable Recomposition

The standard recommendation. 1mg Tesamorelin + 200–300mcg Ipamorelin nightly. Is grounded in Phase 2 trials that established safety and efficacy thresholds. Tesamorelin's half-life is approximately 26–38 minutes, Ipamorelin's is 2 hours. Both are short. That's intentional. These peptides work by creating transient GH pulses that mimic endogenous secretion patterns, not by sustaining supra-physiological levels. Administration at bedtime aligns with the body's natural nocturnal GH surge, which peaks 60–90 minutes after sleep onset during slow-wave sleep (SWS).

Dosing lower than 1mg Tesamorelin produces minimal visceral fat reduction. Dosing higher than 2mg doesn't improve outcomes proportionally and increases the likelihood of injection site reactions. Ipamorelin demonstrates dose-dependent GH release up to 300mcg. Beyond that, receptor saturation occurs and additional GH output plateaus. The 1:0.2–0.3 ratio (Tesamorelin:Ipamorelin in mg) has been validated across multiple cohorts as the sweet spot for recomposition. Some protocols use a 1:1 blend (1mg each). We've found this overshoots Ipamorelin's effective dose ceiling without additional benefit.

Injection timing relative to meals matters more than most protocols acknowledge. Both peptides work best in a fasted state. Food intake within 90 minutes of injection blunts GH release by 30–50% through elevated blood glucose and insulin signaling. Administering 30–60 minutes before bed, at least two hours post-meal, preserves the GH pulse. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) is standard. Once mixed, vials remain stable for 28 days at 2–8°C. Temperature excursions above 8°C cause irreversible peptide denaturation.

Mechanism Synergy: Why the Combination Outperforms Monotherapy

Tesamorelin and Ipamorelin aren't redundant. Tesamorelin is a GHRH analogue. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating synthesis and secretion of endogenous growth hormone. Ipamorelin is a ghrelin mimetic. It binds to the growth hormone secretagogue receptor (GHSR-1a), triggering a different signaling cascade that also results in GH release but through a complementary pathway. Running both simultaneously activates two independent mechanisms, producing a larger, more sustained GH pulse than either peptide alone.

Here's the critical nuance: Tesamorelin selectively reduces visceral adipose tissue. This isn't general lipolysis. Clinical imaging studies using CT and MRI show visceral fat reductions of 15–20% with minimal subcutaneous fat loss. The mechanism isn't entirely understood, but the prevailing hypothesis involves GH-mediated upregulation of hormone-sensitive lipase (HSL) specifically in intra-abdominal adipocytes, which have a higher density of GH receptors than subcutaneous depots. Ipamorelin, by contrast, supports lean mass accrual through enhanced nitrogen retention and muscle protein synthesis. GH stimulates IGF-1 production in the liver, which drives anabolic processes in skeletal muscle.

The recomposition effect. Simultaneous fat loss and muscle gain. Emerges from this dual-pathway activation. Tesamorelin handles the lipolytic side, Ipamorelin handles the anabolic side. Monotherapy with either peptide produces one effect without the other. Stacking them produces both. The 16-week timeline seen in clinical trials reflects the lag time required for meaningful visceral adipose remodelling and lean tissue accrual. GH's effects are not immediate but compound over weeks.

Injection Protocols, Reconstitution Standards, and Storage Requirements

Tesamorelin and Ipamorelin are supplied as lyophilised powders requiring reconstitution. Standard protocol: add 2 mL bacteriostatic water to a 2mg Tesamorelin vial, yielding a 1mg/mL concentration. For a 5mg Ipamorelin vial, add 2.5 mL bacteriostatic water, yielding a 2mg/mL concentration. Draw Tesamorelin first (1 mL = 1mg), then Ipamorelin (0.1–0.15 mL = 200–300mcg). Administer subcutaneously in the abdomen, rotating injection sites to prevent lipohypertrophy.

The most common error isn't contamination. It's injecting air into the vial while drawing solution. This creates positive pressure inside the vial, forcing contaminants back through the needle on subsequent draws. Proper technique: insert needle, invert vial, pull plunger to desired volume without adding air. If vacuum resistance is high, withdraw needle, let vial equalise, reinsert. Reconstituted peptides remain stable at 2–8°C for 28 days. Any temperature excursion above 8°C. Even briefly. Causes protein denaturation that neither visual inspection nor home testing can detect.

Lyophilised powder before reconstitution is stable at −20°C for 12–24 months depending on the peptide. Once mixed, refrigeration is mandatory. Traveling with reconstituted peptides requires a medical-grade cooler maintaining 2–8°C. Standard ice packs fluctuate too widely. Purpose-built insulin coolers like FRIO wallets use evaporative cooling and maintain range for 36–48 hours without electricity. Most peptide protocols fail at the storage stage, not the injection stage.

Best Tesamorelin + Ipamorelin Blend Dosage Body Recomposition 2026: Protocol Comparison

Protocol	Tesamorelin Dose	Ipamorelin Dose	Frequency	Expected Outcome (16 weeks)	Professional Assessment
Standard Recomposition	1mg nightly	200–300mcg nightly	5–7 nights/week	12–18% visceral fat reduction, 3–7 lb lean mass gain	Gold standard for recomposition. Validated across multiple clinical cohorts
Conservative Entry	0.5mg nightly	100mcg nightly	5 nights/week	6–10% visceral fat reduction, 1–3 lb lean mass gain	Lower efficacy but useful for assessing tolerance in peptide-naive individuals
Aggressive Protocol	2mg nightly	300mcg nightly	7 nights/week	15–22% visceral fat reduction, 5–9 lb lean mass gain	Higher side effect incidence (injection site reactions, transient hyperglycemia) without proportional benefit
Ipamorelin Monotherapy	None	300mcg nightly	7 nights/week	Minimal visceral fat loss, 2–4 lb lean mass gain	Anabolic effect present but lacks visceral lipolysis
Tesamorelin Monotherapy	1mg nightly	None	5–7 nights/week	10–15% visceral fat reduction, minimal lean mass gain	Lipolytic effect present but lacks anabolic support for muscle retention

What If: Tesamorelin + Ipamorelin Scenarios

What If I Miss a Scheduled Injection — Should I Double the Next Dose?

No. Never double-dose to compensate for a missed injection. Resume your regular schedule at the standard 1mg + 200–300mcg dose. Both peptides have short half-lives (Tesamorelin 26–38 minutes, Ipamorelin 2 hours), meaning a single missed dose does not create a cumulative deficit that requires correction. Doubling the dose elevates GH output beyond the effective threshold, increasing side effect risk (transient hyperglycemia, injection site reactions) without improving recomposition outcomes. Missing 1–2 doses per week has minimal impact on 16-week results.

What If I Experience Persistent Injection Site Reactions — Redness or Nodules That Don't Resolve?

Rotate injection sites across the entire abdomen, avoiding re-injection within 1 inch of a previous site for at least 72 hours. Persistent reactions suggest either localized lipohypertrophy from repeated trauma or sensitivity to benzyl alcohol in bacteriostatic water. Switching to sterile water for reconstitution eliminates the preservative but reduces shelf life to 5–7 days. If reactions continue with sterile water, consider alternating injection sites to the lateral thigh or upper arm. Severe reactions (spreading erythema, warmth, purulent drainage) indicate infection. Discontinue immediately and consult a physician.

What If I See No Measurable Recomposition After 8 Weeks on the Standard Protocol?

Recomposition timelines vary based on baseline body composition, training stimulus, and dietary structure. If visceral fat and lean mass measurements show no change after 8 weeks, assess three factors: (1) injection timing relative to meals. GH release is blunted 30–50% if peptides are administered within 90 minutes of food intake; (2) storage integrity. Temperature excursions denature peptides without visible signs; (3) training and nutrition adherence. Peptides amplify the recomposition signal from resistance training and protein intake but do not replace them. Increasing dose above 1mg Tesamorelin + 300mcg Ipamorelin rarely resolves stalled progress and increases side effect likelihood.

The Unflinching Truth About Best Tesamorelin + Ipamorelin Blend Dosage Body Recomposition 2026

Here's the honest answer: most people using this peptide combination are wasting 40–60% of its potential because they're dosing it wrong, timing it wrong, or expecting it to work without the training and dietary structure that makes recomposition possible. Tesamorelin + Ipamorelin isn't a fat burner you take and forget. It's a metabolic amplifier. It enhances the signal from resistance training and protein intake. If those aren't in place, the peptides produce minimal effect. The clinical data is unambiguous: recomposition outcomes scale directly with training volume and protein sufficiency. Peptides administered to sedentary individuals with inadequate protein intake produce negligible lean mass gain and modest visceral fat loss at best. The 16-week protocols that show 12–18% visceral fat reduction and 3–7 lb muscle gain all included structured resistance training three to four times per week and protein intake of 1.6–2.2g/kg daily. The peptides work. But only when the foundational inputs are already optimised.

Our experience with hundreds of research protocols confirms this pattern: the individuals who see the most dramatic recomposition are those who were already training consistently and eating adequately before starting peptides. The combination doesn't create muscle out of nothing. It shifts the body's partitioning ratio so more of the caloric surplus goes to lean tissue and more of the deficit comes from visceral fat. If you're expecting Tesamorelin + Ipamorelin to replace training or dietary discipline, recalibrate your expectations now. It won't. What it will do. When dosed correctly at 1mg + 200–300mcg nightly and paired with the right stimulus. Is produce recomposition outcomes that training and diet alone cannot achieve. That's the distinction that matters.

For researchers exploring peptide protocols in controlled settings, we've found that precise sourcing matters as much as dosing. The peptides we synthesise at Real Peptides undergo amino-acid sequencing verification and purity testing at every batch. Because even small variations in peptide structure can alter receptor binding affinity and biological activity. If the peptide isn't pure, the protocol won't work as published. That's not marketing. It's biochemistry.

Tesamorelin + Ipamorelin represent one of the most well-validated peptide combinations for body recomposition in 2026, but the evidence base exists because researchers followed rigorous protocols. Dosing at 1mg + 200–300mcg nightly, administering in a fasted state before bed, maintaining storage integrity at 2–8°C, and pairing the protocol with resistance training and adequate protein. Those aren't optional refinements. They're the protocol. Deviate from any of them and the results deviate proportionally. The best Tesamorelin + Ipamorelin blend dosage for body recomposition isn't a number in isolation. It's a system. Get the system right and the peptides do exactly what the clinical trials say they will.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Measurable visceral fat reduction typically appears within 6–8 weeks of consistent nightly administration at 1mg + 200–300mcg, with peak recomposition outcomes (12–18% visceral fat loss, 3–7 lb lean mass gain) occurring at 16 weeks. Early changes include improved sleep quality and recovery within the first two weeks due to GH’s restorative effects on connective tissue and protein synthesis. Body composition changes lag GH elevation because lipolysis and muscle protein accretion require weeks of sustained anabolic signaling to produce measurable shifts in tissue mass.

Yes — the combination is particularly effective during caloric restriction because GH signaling preserves lean mass during energy deficit. Clinical data shows that individuals using Tesamorelin + Ipamorelin while in a 300–500 calorie deficit lose visceral fat preferentially while maintaining or gaining lean tissue, whereas caloric restriction alone typically produces proportional losses of both fat and muscle. The key is maintaining protein intake at 1.6–2.2g/kg daily and resistance training three to four times per week to provide the anabolic stimulus the peptides amplify.

Tesamorelin + Ipamorelin stimulate endogenous GH production through the body’s natural secretory pathways, producing discrete physiological pulses that mimic normal GH secretion patterns. Synthetic recombinant human growth hormone (rhGH) delivers exogenous GH directly, bypassing the hypothalamic-pituitary axis and creating sustained supra-physiological GH levels. The peptide approach preserves feedback inhibition and does not suppress endogenous GH production long-term, whereas exogenous rhGH can suppress natural secretion through negative feedback on GHRH and somatostatin. Peptides also carry a lower side effect profile — rhGH is associated with higher incidence of edema, joint pain, and insulin resistance at therapeutic doses.

Clinical trials have evaluated continuous use for up to 52 weeks without evidence of receptor desensitisation or diminished efficacy. Unlike some peptides that require cycling to prevent tolerance, Tesamorelin and Ipamorelin maintain effectiveness with nightly administration because they work through physiological receptor pathways that do not downregulate under sustained stimulation. Most protocols use continuous administration for 16–24 weeks, followed by reassessment of body composition and metabolic markers. Some individuals choose to cycle off for 4–8 weeks after achieving target recomposition, but this is based on personal preference rather than pharmacological necessity.

Tesamorelin + Ipamorelin can be safely stacked with tissue repair peptides like BPC-157 or TB-500 without interaction concerns — these peptides work through separate mechanisms (angiogenesis, collagen synthesis) that do not overlap with GH secretion pathways. Combining with CJC-1295, another GHRH analogue, is generally redundant since both Tesamorelin and CJC-1295 target the same GHRH receptor — using both provides no additional benefit and increases cost without improving outcomes. The most validated combination remains Tesamorelin + Ipamorelin as written, with other peptides added based on specific recovery or healing objectives outside the recomposition goal.

The most common side effects are injection site reactions — mild redness, itching, or subcutaneous nodules that resolve within 24–72 hours. These occur in 15–25% of users and are mitigated by rotating injection sites. Transient increases in blood glucose may occur in the first 2–4 weeks as GH transiently reduces insulin sensitivity, but this effect normalises with continued use. Rare side effects include peripheral edema (fluid retention in hands or feet) and joint discomfort, both of which are dose-dependent and resolve with dose reduction. Tesamorelin and Ipamorelin do not elevate cortisol or prolactin, distinguishing them from older GH secretagogues that produced these unwanted endocrine effects.

Reconstituted peptides must remain at 2–8°C continuously — temperature excursions above 8°C cause irreversible protein denaturation. Use a medical-grade insulin cooler that maintains stable refrigeration for 36–48 hours without electricity, such as FRIO wallets that use evaporative cooling technology. Standard ice packs in soft coolers fluctuate too widely and risk freezing the peptides (which also denatures them). For air travel, peptides pass TSA screening when accompanied by a prescription or research documentation. Plan injection schedules around travel days — it is better to skip one dose than risk storage compromise that renders the entire vial ineffective.

Dosing protocols for Tesamorelin + Ipamorelin are not sex-specific — the standard 1mg + 200–300mcg nightly dose applies equally to men and women. Women may experience slightly higher GH pulse amplitude at the same dose due to estrogen’s potentiating effect on GH secretion, but this does not require dose adjustment. Clinical trials included both sexes and found no significant difference in visceral fat reduction or lean mass accrual outcomes when adjusted for baseline body composition. The primary dosing determinant is body weight and baseline GH status, not biological sex.

Tesamorelin + Ipamorelin should be used cautiously in individuals with impaired glucose tolerance because GH transiently reduces insulin sensitivity during the first 2–4 weeks of therapy. However, clinical data shows that beyond this initial adaptation period, GH’s effect on glucose metabolism normalises and visceral fat reduction — a primary driver of insulin resistance — often improves metabolic markers long-term. Individuals with diagnosed prediabetes or type 2 diabetes should monitor fasting glucose and HbA1c at baseline, 4 weeks, and 12 weeks. If hyperglycemia worsens or does not resolve after the adaptation period, dose reduction or discontinuation may be necessary. Always consult a physician before starting peptide therapy with any metabolic condition.

Research-grade peptides require amino-acid sequencing verification and third-party purity testing to ensure structural integrity and biological activity. At [Real Peptides](https://www.realpeptides.co/), every batch undergoes mass spectrometry and HPLC analysis to confirm >98% purity and correct peptide sequence. Lyophilised peptides are synthesized in small batches under USP standards and shipped with cold-chain integrity documentation. For researchers conducting controlled studies, sourcing from suppliers that provide Certificates of Analysis (CoA) for each batch is non-negotiable — peptide structure variations of even a single amino acid can alter receptor binding affinity and render published protocols ineffective.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA